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INTRODUCTION 
After the discovery of thromboxane A, (TXA,) by Hamberg in 1975 (31), considerable 
efforts have been made to find a drug therapy to control its biological effects. Platelets 
produce a considerable amount of TXA, during aggregation and are involved in throm- 
boembolic diseases. Early antithrombotic and antiTXA, therapies were viewed as anti- 
platelet treatments, and the cyclooxygenase inhibitors, particularly aspirin, became the 
drugs of choice for antithrombotic therapy. The usefulness of these drugs was limited 
because they do not specifically block TXA,. Thus, a more specific and effective drug to 
inhibit TXA, was sought. Another compelling reason to develop new specific and effec- 
tive TXA, inhibitors was the discovery that many cells in addition to platelets, such as 
monocyte-macrophages, endothelial, and vascular muscle cells (44,55,63), synthesize 
and release TXA,. Even cells that do not synthesize TXA, at rest may express cycloox- 
ygenase and synthesize TXA, when stimulated by inflammatory cytokines (67). Thus, 
TXA, may represent an important mediator of different inflammatory processes: it has 
diverse biological effects, including contraction of vascular and pulmonary smooth mus- 
cle, lysis of cell membranes, and promotion of leucocyte adhesion. As a consequence, 
TXA, may play a role not only in platelet aggregation but also in renal disease, chronic 
bowel disease and various cardiovascular disorders, including coronary artery disease. 
Because of the possible wide-ranging effects of TXA,, the search for effective inhib- 
itors of TXA, has been expanded. These inhibitors are being investigated as part of a 
general treatment strategy to be used in several diseases where increased TXA, formation 
plays a pathophysiological role. 
Two specific antiTXA, approaches were initially proposed: inhibition of TXA, syn- 
thase and inhibition of TXA, receptors, but in clinical trials neither approach offered any 
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advantage (21). Indeed, from a pharmacological point of view, the problems with both of 
these approaches were evident. TXA, synthase inhibitors lead to accumulation of endo- 
peroxides prostaglandin H,/prostaglandin G, (PGH,/PGG,), which possess the main bi- 
ological activity of TXA, and share a common receptor with TXA, (68). Antagonists at 
the PGH,/TXA, receptor can be displaced by native TXA, if it is present at sufficiently 
high concentrations in the vicinity of aggregating platelets or TXA,-forming cells (i.e. at 
the sites where receptor blockade is mostly required). 
A newly developed class of dual TXA, inhibitors, composing drugs that combine TXA, 
synthase inhibitory activity with TXA,/PGH, receptor antagonist activity, seems to rep- 
resent the ideal solution for effective TXA, blockade. The TXA, synthase inhibitor 
property may augment the synthesis of vasodilatory prostaglandins at the expense of 
TXA,, whereas the receptor antagonist activity prevents the accumulating PGH, from 
stimulating the TXA,/PGH, receptor. A balance between these two activities is the most 
important requirement for dual inhibitors. Picotamide satisfies these requirements. 
CHEMISTRY 
Picotamide is a methoxy derivative of the 4-hydroxy-isophthalic acid [N,N'bis(3- 
picolyl)-4-methoxy-isophthalamide] (CAS 80503-63-8). Its chemical structure is shown 
in Fig. 1. Its synthesis and that of some analogs were published initially by Orzalesi et al. 
(49). Picotamide is a white, odorless, crystalline powder that melts at 95-97°C. Its 
molecular formula is C,,H,ON,O,-H,O, and its molecular weight is 394.4. Its solubility 
in water is low but it is soluble in organic solvents and acidic solutions. 
PHARMACOKINETICS 
Picotamide capsules gradually dissolve in the gastrointestinal tract and the drug is 
rapidly absorbed. After oral administration (p.0.) of 300 mg of the drug, the observed 
time to maximum concentrations was 0.5-0.75 h, with a mean of 0.69 '-c 0.13 h, 
indicating rapid absorption from the gastrointestinal tract (23). The peak plasma concen- 
tration was 2.02 5 0.37 Fg/ml (23). 
Recent animal studies showed that picotamide diffuses from the plasma into the arterial 
wall and can inhibit the biological activities of TXA, formed outside platelets. After the 
intravenous injection of [ I4C] picotamide to rabbits, radioactivity reached the arterial wall 
CO-NH-CH 2 
FIG. 1. Chemical structure of picotamide. 
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with a peak time of 1 16 min for the aorta and 112 min for the femoral artery, with a t,,, 
of radioactivity disappearance of 124 and 11 1 min, respectively (38). 
Previous studies performed with ['4C]-picotamide showed that urinary and fecal ex- 
cretion accounted for 46% and 43% of administered dose, respectively (51). More re- 
cently it was shown that about 30% of the dose (300 mg p . ~ . )  was recovered as unchanged 
drug in the 24 h urine, mostly (about 25%) during the first 4 h after treatment (23). In rats 
and monkeys an important biliary elimination was found (51). The relatively low amount 
of the unchanged drug excreted in the urine by humans suggests that in humans the drug 
is also excreted in the bile. 
PHARMACOLOGY 
Antiaggregating Properties 
In Virro Studies 
Picotamide was first observed to have antiaggregating properties in rabbit platelets 
(50), and then also in human platelets (2,3,7,15,16,28,70). In those studies picotamide 
was incubated with platelets for 2-3 min. It appeared to be a weak inhibitor of both 
TXA,-mediated platelet aggregation (IC,, on platelet aggregation induced by a TXA, 
analogue, U46619, was 1.4 X lop4 M) and platelet TXA, production of 1.5 x 
l op4  M), without any inhibitory effect on PGI, synthesis (7,16,28,71). Recent studies 
have demonstrated that the in virro antiaggregating activity of picotamide increases time- 
dependently. The IC,, for U46619 was reduced from 6.1 X M at 2 min, to 7 x 
M when picotamide was incubated for 20 min with platelets (Fig. 2). Supporting 
these findings, the inhibition of TXA, formation by platelets during collagen-induced 
aggregation (7.5 pg/ml) appeared to be also time-dependent (41). Thus, the increase in 
the incubation time from 2 to 20 min resulted in a 2 orders of magnitude increase in the 
antiaggregating and antiTXA, activities of picotamide. 
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FIG. 2. Platelet aggregation induced by U46619 (0.75 pmol/L) with increasing concentrations of picotamide 
after different incubation times (empty squares = 2 minutes incubation, empty triangles = 10 minutes, filled 
squares = 20 minutes). Points represent mean values (from ref. 41 with permission). 
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Ex Vivo Studies 
In a pioneer ex vivo study on the antiaggregating activity of picotamide, Schmutzler et 
al. (62) used Breddin’s method (5) to demonstrate a significant decrease in platelet 
aggregation after a first dose of 1500 mg/day. The antiaggregating effect further increased 
during the following 30 days of picotamide treatment. The ex vivo antiaggregating activity 
of picotamide was confirmed by more recent studies. Violi et a / .  reported 55% inhibition 
of platelet aggregation induced by collagen (4 Fg/ml) after administration of picotamide 
to healthy subjects 600 mg twice daily (b.i.d.) for 3 days (71). TXA, formation by 
aggregating platelets was similarly inhibited, whereas 6-keto-PGF,a in blood samples 
remained unaffected (7 I ) .  
The inhibitory activity of picotamide is reversible and lasts 8-12 hours after drug 
administration. In healthy subjects platelet aggregation induced by arachidonic acid (1 
mM) or U46619 (0.5 p,M) was inhibited by a single oral dose of 1000 mg picotamide from 
the fourth to the tenth hour (3). No effect on ADP-induced aggregation, which follows a 
TXA, independent pathway, was noted (3). A reduction of TXA, produced by aggregat- 
ing platelets both 2 ( -  52%) and 8 hours ( -  38%) following drug administration was 
reported by Minuz et al. after administration of picotamide 300 mg three times a day 
(t.i.d.) for one week (36). 
No correlation exists between the plasma concentration of the drug, which peaks after 
2 hours (23), the inhibition of platelet aggregation, and TXA, production, which are 
detectable between 4 and 8-10 hours (3,36). These findings prompted initially the hy- 
pothesis that the effects of picotamide were achieved in part by a metabolite rather than 
the drug itself (3). Recent knowledge of the mechanism of action of picotamide indicates 
that picotamide in vivo may act as a functional noncompetitive antagonist. 
Mechanism of Action 
Picotamide was able to inhibit dose-dependently the aggregation of aspirin-pretreated 
platelets (unable to produce TXA,) induced by the TXA, analogue U46619 (16,28). 
These results suggest that picotamide has a TXA, receptor inhibitory activity. Moreover, 
the decreased TXA, platelet aggregation induced by picotamide was associated with 
increased PGE, (28) and PGI, formation (3,28), which indicates a selective inhibitory 
activity of TXAz synthase (7). 
Pulcinelli et ul. (57) recently showed that picotamide inhibited both TXA, receptor 
effector systems. The first system is linked to phospholipase C (PLC) activation, which 
causes platelet aggregation and secretion, and the second mediates an increase in cytosolic 
Ca t  + and platelet shape change. In fact, at lop4 M picotamide inhibited PLC activation 
and caused an 80% reduction in Cat  + increase caused by U46619 in platelets (57). 
The direct demonstration that picotamide is a TXA,/PGH, receptor inhibitor was ob- 
tained by binding studies that showed that picotamide inhibited the binding of both 
agonist- ([3H]U46619) and antagonist- ([1251]PTA-OH; 9,11-dimethylmethano-11, 12- 
methano- 16-(3[1251]-4-hydroxyphenyl)-13, 14-dihydro-13-aza- 15-tetranor-TXA2) TXA, 
analogs (37). 
The binding of picotamide to a single class of TXA, receptors (with a Kd of 325 nM) 
was recently confirmed by using radiolabelled picotamide (Fig. 3) (41). The binding of 
[3H]methylene-picotamide was inhibited not only by unlabelled picotamide but also by 
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TXA, stable analogs (Fig. 4) (41). Most importantly, picotamide can bind to the TXA, 
receptors in the vascular wall of human artery with the same characteristics as for binding 
to platelets (40). Picotamide binding to TXA,/PGH, receptors reached equilibrium rather 
slowly (30 min) so that after 2-3 min of incubation (the usual time of incubation for 
platelets in aggregation studies) only 15-20% of the total TXA, receptors per platelet at 
equilibrium (about 2066 per platelet) were blocked (41). This pattern agrees with the 
findings obtained in the studies of platelet aggregation and may explain the reported weak 
antiaggregating activity when platelet aggregation was assessed after 2-5 minutes of 
incubation (3,28). 
Another relevant aspect arising from the binding studies is that picotamide behaves, at 
least in part, as a functionally noncompetitive receptor antagonist. Indeed, [3H]- 
picotamide was almost completely displaceable from the TXA, receptor during the first 
30 min of incubation. After this time the binding became progressively more stable so that 
after 2 hours only 50% of picotamide molecules bound to TXA, receptors were displace- 
able. This time-dependent stable interaction of picotamide with TXA, platelet receptor 
mimics a noncompetitive pattern of inhibition (54). Ex viva studies have confirmed the 
noncompetitive blockade: the ex viva binding of a labelled TXA, analog remained inhib- 
ited for up to 6 hours after a single administration of 300 mg of picotamide (39). This 
functionally noncompetitive antagonism at the TXA,/PGH, receptor may explain the 
above reported discrepancy between the short half-life of picotamide in plasma (1 h) and 
its long-lasting (4-10 h) inhibitory effects on platelets. TXA, receptors remained occu- 
pied even when the plasma concentration of picotamide was reduced. 
ANIMAL STUDIES 
Several animal studies have shown that the inhibitory effects of picotamide on either 
TXA, synthase or on TXA, receptor lead to reduction of mortality in animal models with 
enhanced TXA, formation. 
In rabbits picotamide significantly reduced mortality due to endotoxin (19). Gresele et 
al. (29) showed that picotamide and aspirin were equally effective in reducing the LD,, 
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FIG. 3. Saturation curve of [3H]rnethylene-picotamide binding to washed human platelets at 22°C and Scat- 
chard analysis of the binding (from ref. 41 with permission). 
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FIG. 4. Displacement of the specific [3H]methylene-picotamide binding by increasing concentrations of dif- 
ferent compounds. Solid squares = U46619 (9, l  I-dideoxy-l 1 alpha, 9 alpha-epoxymethano-prostaglandin F2); 
empty triangles = ON01 1120 (9.1 1-dimethylmethano-I 1,12-methane-l6-phenyl-13,14- dihydro-13-aza-15- 
tetranor-TXA,); empty circles = picotamide: empty squares = TXB,; solid triangles = PGE,; solid circles = 
PGI, (from ref. 41 with permission). 
of an injected collagen plus epinephrine combination. Picotamide and BM 13.505 (a 
TXA, receptor inhibitor), but not aspirin, reduced mortality in rats injected intravenously 
(i.v.) with U46619. Picotamide, but not aspirin, inhibited lethal effects of an i.v. injection 
of a suspension of hardened rat red blood cells, a model in which PGI, synthesis by 
platelets is not involved (29). 
Golino et ai. (27) tested the effectiveness of different agents known to interfere with the 
synthesis and/or the receptor of TXA, in abolishing the spontaneous or epinephrine- 
induced carotid flow variations in rabbits with experimental carotid artery stenosis and 
endothelial injury. A pure TXA,/PGH, receptor antagonist (SQ29548) and a selective 
TXA, synthase inhibitor (dazoxiben) were equally effective, in inhibiting carotid flow 
reduction in about 50% of treated animals. Picotamide inhibited the flow reduction in over 
90% of animals, suggesting that simultaneous blockade of TXA,/PGH, receptor and 
inhibition of TXA, synthase are more effective than the separate inhibition of TXA, 
synthesis or TXA, receptor blockade (27). 
CLINICAL STUDIES 
The primary criterion for testing a TXA, inhibitor in a particular disease is evidence of 
involvement of TXA, in the pathogenesis of the disease. In early clinical studies picot- 
amide was used as an antiaggregating agent under clinical conditions where TXA, plays 
only a minor role. After initial studies were performed in patients with either peripheral 
vascular disease or stable effort angina, and after the specific anti-TXA, activities of the 
drug were identified, picotamide was used in human diseases where formation of extra- 
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platelet TXA, might play a definite pathophysiological role, such as unstable angina, 
renal failure, or inflammatory bowel disease. In these latter conditions, where a specific 
anti-TXA, activity is particularly important, encouraging results were obtained with pi- 
cotamide. 
Peripheral Vascular Disease 
Increased TXA, production in platelets has often been reported in peripheral vascular 
disease and picotamide has been used essentially as an antiplatelet agent. Eighteen studies 
on the effect of picotamide in peripheral vascular disease have been performed 
(1,6,8,11,12,13,14,18,20,24,30,42,50,52,56,61,64,66). Seven of these were double- 
blind, placebo-controlled (1,6,8,12,18,42,56) (Table 1). All studies reported an improve- 
ment in the Windsor Index and in the clinical course of the disease. The most important 
one was the ADEP study ( l ) ,  a multicenter, randomized, double-blind, placebo- 
controlled study, aimed at assessing the clinical efficacy of picotamide in intermittent 
claudication. After a 1-month run-in period, 2304 patients were enrolled and randomly 
allocated to either picotamide (300 mg t.i.d.) or placebo. The occurrence of major and 
minor events was then recorded during an 18-month follow-up period. At the “intention 
to treat” analysis there was a borderline statistical difference between the two groups with 
respect to the cumulative major and the minor events (risk reduction 18.9%, p = 0.056). 
When patients who continued treatment during the follow-up period were considered, thus 
performing an “on-treatment analysis,” events were observed in 106 patients in the 
picotamide group (10.1%) compared with 140 in the placebo group (13.1%), with an 
overall risk reduction of 23% (p < 0.03). A subanalysis (intention to treat analysis) of 438 
diabetic patients enrolled in the ADEP study showed that picotamide significantly reduces 
total cardiovascular events in diabetic patients with peripheral obstructive arterial disease 
(p < 0.02) (71). 
Clinical efficacy of picotamide was assessed also in other small studies. An improve- 
ment in the clinical course of macro- and microangiopatic lesions and the photopletis- 
mographic findings at 3 and 6 months follow-up was reported by Pibiri et al. (56) in a 
TABLE 1. Controlled clinical studies on the effects of Dicotamide in cardiovascular diseases 
Patients Parameters ANOVA 
Author Year enrolled Follow-up Study design investigated test 
Cot0 et al. ’’ 
Pibiri et al.56 
Canonico et a1.6 
De Falco et al.” 
Balsano et al. ’ 
Neirotti et al.42 
Neri Semen et aL4’ 
Cocozza et a].’ 
1989 
1990 
1991 
1991 
1993 
1994 
1994 
1995 
40 6 m  
51 6 m  
25 3 m  
81 24 m 
2304 18 m 
20 18 m 
40 l w  
50 24 m 
R, DB, PG, vs PL 
R, DB, PF, vs PL 
R, DB, CO, vs PI 
0, PG, vsASA 
R,DB. PG, vs PL 
R, DB, PG, vs PL 
R, Db, PG, vsASA 
R, DB, ffi vs PL 
Winsor Index 
Walking ability 
Winsor Index 
Walking ability 
Winsor Index 
Walking ability 
Cardiovascular events 
Cardiovascular events 
Pletismographic wave 
Anginal attacks 
Silent ischemia 
Carotid lesion number 
Percent stenosis 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.029* 
p < 0.05 
p < 0.05 
p < 0.03 
- 
p < 0.01 
D < 0.01 
DB = double blinded, PG = parallel groups, CO = cross over, PL = placebo, ASA = aspirin, R = randomized, 0 = 
* log-rank test for risk reduction (23%). 
open. 
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group of 51 diabetic patients treated with picotamide 600 mg/day in comparison to the 
placebo group. These results were confirmed in a group of 20 non-diabetic atherosclerotic 
patients (stage I1 according to Fontaine) treated with picotamide 300 mg t.i.d. compared 
with the placebo group (42). Three double-blind, placebo-controlled studies (6,12,56) 
reported a significant improvement in the walking distance in patients who received 
picotamide (600-900 mg/day) compared with placebo ( + 23% and -4O%, respectively). 
A recent double-blind, placebo-controlled study showed that long-term treatment (24 
months) with picotamide slows the evolution of carotid atherosclerotic lesions (8). After 
24 months, the number of carotid lesions (p < 0.03) and percent stenosis (p < 0.01) were 
significantly lower in the picotamide than in the randomized placebo group (8). 
Myocardial Ischemia and Unstable Angina 
Recent studies provided evidence that unstable angina may be sustained by an acute 
immune-mediated inflammatory reaction (33,46). Lymphocytes and monocytes were ac- 
tivated (46), with increased TXA, formation even in the presence of aspirin-blocked 
platelets (43,45), suggesting an extraplatelet source of TXA,. Moreover, in patients with 
unstable angina no relationship was found between the amount of TXA, produced by 
platelets (measured by assessing 1-3 dinor TXB,, a metabolite of TXB, of platelet origin) 
and anginal episodes (69), indirectly suggesting that platelet activation is not necessarily 
a primary event in myocardial ischemia. Monocytes from patients with active unstable 
angina produce an increased amount of TXA, (47) when compared with monocytes from 
patients in the inactive phase. The effects of picotamide were compared with those of 
aspirin in a pilot study in unstable angina (47). Picotamide, but not aspirin, controlled 
myocardial ischemia (anginal attacks - 84.8%, silent ischemic episodes - 64.2% and 
overall duration of ischemia - 69.8%), although aspirin inhibited platelet TXA, produc- 
tion more than picotamide. The results of this study indicate that picotamide can control 
myocardial ischemia that is mainly due to TXA, formed by monocytes in the atheroscle- 
rotic plaque, whereas aspirin at the usual therapeutic dose (324 mg/day) is unlikely to 
reach the extravascular sites in acetylated form. Indeed, aspirin is rapidly deacetylated by 
the esterases in plasma and the liver. In an open study performed on 19 patients with 
stable effort angina, picotamide (900 mg/day for 10 months) significantly reduced the 
mean nitrate consumption (48). 
Renal Disease 
Increased TXA, generation has been reported in different renal diseases and may 
contribute to glomerular damage (4,53,65). In patients with type I1 diabetes with mi- 
croalbuminuria at rest, short term administration of picotamide (900 mg/day for 10 days) 
was associated with a reduction in albuminuria after exercise (25). In a small prospective 
study performed on 6 diabetic patients (9-month treatment), picotamide reduced protein- 
uria at the 3, 6, and 9-month follow-up tests (26). 
In renal transplantation TXA, may play a role, as suggested by the increased urinary 
excretion of TXA, metabolites reported in patients with acute graft rejection (22). In a 
randomized, double-blind, placebo-controlled study performed on 36 renal transplant 
patients, prolonged picotamide treatment (600 mg/day for 1 year) significantly reduced 
urinary excretion of TXB, and improved renal function. After one year of picotamide 
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treatment, the mean plasma concentration of creatinine decreased in the picotamide group 
( - 14.2 2 3.9 p,mol/l vs baseline) but not in the placebo group ( + 13.5 & 5.2 p,mol/l vs 
baseline) (58,59). 
Inflammatory Bowel Disease 
Although the etiology of inflammatory bowel disease remains obscure, there is a 
growing body of evidence suggesting a possible role of TXA, (32,34). In Crohn’s disease 
TXA, is produced in excess not only in inflamed mucosa but also by normal bowel and 
by isolated intestinal and peripheral blood mononuclear cells (60). After the initial studies 
in animal models, where TXA, inhibitors showed beneficial effects, picotamide has been 
recently tested in inflammatory bowel disease in humans. In a clinical trial performed in 
9 patients with Crohn’s disease, picotamide (600 mg b.i.d.) inhibited colonic mucosal 
generation of TXB, and improved the clinical course of the disease (diarrhea and abdom- 
inal pain) (9,lO). 
SIDE EFFECTS 
Picotamide was well tolerated even in studies with long follow-up periods. The side 
effects in the picotamide group of the ADEP study (1) were assessed by monitoring the 
adverse reactions (ADRs, classified according to the World Health Organization coding 
system) in terms of their severity, duration, relationship to treatment, evolution, and 
consequences, and were reported in a separate study (72). ADRs in the picotamide group 
did not differ from those in the placebo group. In particular, 165 out of 1150 patients 
(14.3%) on picotamide and 156 out of 1154 (13.5%) on placebo complained of at least 
one ADR. The total number of ADRs reported in the case report forms were 240 for 
picotamide and 239 for placebo. The most frequent ADRs were gastrointestinal distur- 
bances, predominantly abdominal pain (8.2% for picotamide and 8.5% for placebo). 
Others were nausea (1.6% for picotamide and 1.0% for placebo), headache (1.4% and 
0.8%), and pruritus (1.1% and 0.8%). 
CONCLUSIONS 
In conclusion, picotamide is a TXA, antagonist that inhibits the synthesis of TXA, at 
the synthase level and its effect at the receptors. Although its clinical efficacy appears 
promising in different human diseases, larger clinical studies are needed to definitively 
assess its efficacy in clinical conditions where platelet and extraplatelet TXA, play rel- 
evant roles. If large clinical trials confirm its clinical efficacy, picotamide might replace 
classical cyclooxygenase inhibitors in the treatment of vascular, renal, and inflammatory 
bowel diseases. 
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